A 67-Year-Old-Man with Metastatic Prostate Cancer - Episode 5

Unmet Needs, Future Directions, and Clinical Pearls in mCRPC

Dr. Freedland closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing some clinical pearls for community oncologists treating patients with the disease.

EP. 1: Case Presentation: A 67-Year-Old-Man with Metastatic Prostate Cancer
EP. 2: Available Systemic Therapy Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy
EP. 3: Factors for Consideration When Selecting Treatments for Patients with mCRPC
EP. 4: The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer
Now Viewing
EP. 5: Unmet Needs, Future Directions, and Clinical Pearls in mCRPC